Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Beginning Cash Balance: 2022-2024

  • Summit Therapeutics' Beginning Cash Balance was N/A to $75.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $200.7 million, marking a year-over-year change of. This contributed to the annual value of $100.0 million for FY2024, which is 305.09% up from last year.
  • According to the latest figures from Q4 2024, Summit Therapeutics' Beginning Cash Balance is $75.5 million, which was down 0.00% from $75.5 million recorded in Q3 2024.
  • In the past 5 years, Summit Therapeutics' Beginning Cash Balance registered a high of $75.5 million during Q3 2024, and its lowest value of $24.7 million during Q1 2023.
  • In the last 3 years, Summit Therapeutics' Beginning Cash Balance had a median value of $50.2 million in 2022 and averaged $50.2 million.